Abstract
Despite its low incidence, stent thrombosis (ST) is one of the most dreaded complications of percutaneous coronary intervention. Endeavor (Medtronics Europe SA) is a new zotarolimus-eluting stent (ZES) with a favorable safety profile that was reported in early and ongoing trials. However, few lethal stent thromboses related to this new drug eluting stent (DES) have been reported. We experienced a case of simultaneous subacute ZES thromboses, 6 days after stent implantations in the proximal left anterior descending artery and the proximal right coronary artery (RCA).
Original language | English |
---|---|
Pages (from-to) | 243-246 |
Number of pages | 4 |
Journal | Korean Circulation Journal |
Volume | 40 |
Issue number | 5 |
DOIs | |
Publication status | Published - 2010 May |
Externally published | Yes |
Keywords
- Drug-eluting stents
- Stents
- Thrombosis
- Zotarolimus
ASJC Scopus subject areas
- Internal Medicine
- Cardiology and Cardiovascular Medicine